Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy | Zendy

George K. Siberry | Zendy; Denise L. Jacobson | Zendy; Heidi J. Kalkwarf | Zendy; Julia Wu | Zendy; Linda A. DiMeglio | Zendy; Ram Yogev | Zendy; Katherine M. Knapp | Zendy; Justin Wheeler | Zendy; Laurie Butler | Zendy; Rohan Hazra | Zendy; Tracie L. Miller | Zendy; George R. Seage | Zendy; Russell B. Van Dyke | Zendy; Emily Barr | Zendy; Mariam Davtyan | Zendy; Lynne Mofenson | Zendy; Kenneth Rich | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy

Author(s) -

George K. Siberry,

Denise L. Jacobson,

Heidi J. Kalkwarf,

Julia Wu,

Linda A. DiMeglio,

Ram Yogev,

Katherine M. Knapp,

Justin Wheeler,

Laurie Butler,

Rohan Hazra,

Tracie L. Miller,

George R. Seage,

Russell B. Van Dyke,

Emily Barr,

Mariam Davtyan,

Lynne Mofenson,

Kenneth Rich

Publication year - 2015

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/civ437

Subject(s) - medicine , tenofovir , pregnancy , gestation , gestational age , in utero , obstetrics , confidence interval , birth weight , fetus , human immunodeficiency virus (hiv) , immunology , genetics , biology

Fetal bone effects of maternal tenofovir use have not been well studied. We sought to compare whole-body bone mineral content (BMC) of newborns exposed vs not exposed to tenofovir in utero.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research